<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05093634</url>
  </required_header>
  <id_info>
    <org_study_id>RM-493-035</org_study_id>
    <nct_id>NCT05093634</nct_id>
  </id_info>
  <brief_title>EMANATE: Phase 3 Study of Setmelanotide in Patients With POMC, PCSK1, LEPR, SRC1, SH2B1, or PCSK1 N221D Genetic Variants</brief_title>
  <official_title>A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study: 5 Independent Sub-studies of Setmelanotide in Patients With POMC, PCSK1, LEPR, SRC1, SH2B1, or PCSK1 N221D Gene Defects in the Melanocortin-4 Receptor Pathway</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rhythm Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Rhythm Pharmaceuticals, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The protocol describes a randomized, double-blind, placebo-controlled trial with 5&#xD;
      independent sub-studies of setmelanotide in patients with obesity and at least one of 6&#xD;
      specific gene defects in the Melanocortin-4 Receptor pathway:&#xD;
&#xD;
        -  POMC or PCSK1 (Sub-study 035a)&#xD;
&#xD;
        -  LEPR (Sub-study 035b)&#xD;
&#xD;
        -  SRC1 (Sub-study 035c)&#xD;
&#xD;
        -  SH2B1 (Sub-study 035d)&#xD;
&#xD;
        -  PCSK1 N221D (Sub-study 035e)&#xD;
&#xD;
      These 5 sub-studies have high degree of similarities. The objectives and endpoints are&#xD;
      identical for all 5 sub-studies.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">December 2021</start_date>
  <completion_date type="Anticipated">December 2024</completion_date>
  <primary_completion_date type="Anticipated">September 2024</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Primary Outcome (Identical for all 5 Sub-Studies)</measure>
    <time_frame>From baseline to 52 weeks of treatment</time_frame>
    <description>Mean change in body weight in patients treated with Setmelanotide compared to Placebo</description>
  </primary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Anticipated">560</enrollment>
  <condition>Patients With Obesity and Specific Gene Defects in the Melanocortin-4 Receptor Pathway</condition>
  <arm_group>
    <arm_group_label>POMC or PCSK1 genetic variant</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>1:1 Randomization</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LEPR genetic variant</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>1:1 Randomization</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SRC1 genetic variant</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>1:1 Randomization</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SH2B1 genetic variant</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>1:1 Randomization</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PCSK1 N221D genetic variant</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>1:1 Randomization</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Setmelanotide</intervention_name>
    <description>Subcutaneous Injection</description>
    <arm_group_label>LEPR genetic variant</arm_group_label>
    <arm_group_label>PCSK1 N221D genetic variant</arm_group_label>
    <arm_group_label>POMC or PCSK1 genetic variant</arm_group_label>
    <arm_group_label>SH2B1 genetic variant</arm_group_label>
    <arm_group_label>SRC1 genetic variant</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Subcutaneous Injection</description>
    <arm_group_label>LEPR genetic variant</arm_group_label>
    <arm_group_label>PCSK1 N221D genetic variant</arm_group_label>
    <arm_group_label>POMC or PCSK1 genetic variant</arm_group_label>
    <arm_group_label>SH2B1 genetic variant</arm_group_label>
    <arm_group_label>SRC1 genetic variant</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patients must have a pre-identified:&#xD;
&#xD;
               -  Heterozygous genetic variant in the POMC gene or PCSK1 gene (Sub-study 035a)&#xD;
&#xD;
               -  Heterozygous genetic variant in the LEPR gene (Sub-study 035b),&#xD;
&#xD;
               -  Homozygous, heterozygous, or compound heterozygous variant in the SRC1 (Sub-study&#xD;
                  035c),&#xD;
&#xD;
               -  Homozygous, heterozygous, or compound heterozygous variant in SH2B1 gene, or&#xD;
                  chromosomal 16p11.2 deletion encompassing the SH2B1 gene (Sub-study 035d),&#xD;
&#xD;
               -  Heterozygous N221D variant in the PCSK1 gene (Sub-study 035e).&#xD;
&#xD;
          2. Between 6 and 65 years of age at the time of provision of informed consent/assent.&#xD;
&#xD;
          3. Obesity, defined as BMI ≥30 kg/m2 for patients ≥18 years of age or BMI ≥95th&#xD;
             percentile for age and gender for patients 6 up to 17 years of age, based on the&#xD;
             United States (US) Centers for Disease Control and Prevention criteria.&#xD;
&#xD;
          4. Patient and/or parent or guardian is able to communicate well with the Investigator,&#xD;
             understand and comply with the requirements of the study (including once daily [QD]&#xD;
             injection regimen and all other study procedures), and is able to understand and sign&#xD;
             the written informed consent/assent. Patients who are unable to comply with all study&#xD;
             procedures due to cognitive limitations or any other reason should not be enrolled&#xD;
             into the study.&#xD;
&#xD;
          5. Patient and/or parent or guardian reports that patient experienced childhood obesity,&#xD;
             defined as the patient and/or parent or guardian reporting that the patient was&#xD;
             significantly overweight during childhood.&#xD;
&#xD;
          6. For women of child-bearing potential (WOCBP), agrees to use a highly effective form of&#xD;
             contraception throughout the study and for 90 days following the study.&#xD;
&#xD;
          7. Reported history of lifestyle intervention of diet and exercise.&#xD;
&#xD;
          8. Reported history of hyperphagia.&#xD;
&#xD;
        Key Exclusion Criteria (Partial list):&#xD;
&#xD;
          -  Weight loss of 2% or greater in the previous 3 months.&#xD;
&#xD;
          -  Recent history of bariatric surgery.&#xD;
&#xD;
          -  Significant psychiatric disorder(s).&#xD;
&#xD;
          -  Suicidal ideation, attempt or behavior.&#xD;
&#xD;
          -  Clinically significant pulmonary, cardiac or oncologic disease that may interfere with&#xD;
             the study and/or confound the results.&#xD;
&#xD;
          -  Glycated hemoglobin (HbA1C) &gt;10% at Screening.&#xD;
&#xD;
          -  History of significant liver disease or severe kidney disease.&#xD;
&#xD;
          -  History or close family history (parents or siblings) of melanoma, or patient history&#xD;
             of oculocutaneous albinism.&#xD;
&#xD;
          -  Significant dermatologic findings relating to melanoma or pre-melanoma skin lesions&#xD;
             (excluding non-invasive basal or squamous cell lesion).&#xD;
&#xD;
          -  Patient is, in the opinion of the Study Investigator, not suitable to participate in&#xD;
             the study.&#xD;
&#xD;
          -  Participation in any clinical study with an investigational drug/device within 3&#xD;
             months or 5 half-lives, whichever is longer, prior to the first day of dosing.&#xD;
&#xD;
          -  Previously enrolled in a clinical study involving setmelanotide or any previous&#xD;
             exposure to setmelanotide.&#xD;
&#xD;
          -  Significant hypersensitivity to any excipient in the study drug.&#xD;
&#xD;
          -  If female, pregnant or breastfeeding.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Linda Shapiro, MD PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Rhythm Pharmaceuticals, Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Patient Inquiry: Patient Advocacy</last_name>
    <phone>(857) 264-4280</phone>
    <email>patientadvocacy@rhythmtx.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Physician Inquiry: Clinical Trials</last_name>
    <phone>(857) 264-4280</phone>
    <email>clinicaltrials@rhythmtx.com</email>
  </overall_contact_backup>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>September 30, 2021</study_first_submitted>
  <study_first_submitted_qc>October 13, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 26, 2021</study_first_posted>
  <last_update_submitted>October 13, 2021</last_update_submitted>
  <last_update_submitted_qc>October 13, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 26, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Melanocortin-4 Receptor Pathway</keyword>
  <keyword>Genetic Obesity</keyword>
  <keyword>Hunger</keyword>
  <keyword>Hyperphagia</keyword>
  <keyword>POMC</keyword>
  <keyword>PCSK1</keyword>
  <keyword>LEPR</keyword>
  <keyword>SRC1</keyword>
  <keyword>SH2B1</keyword>
  <keyword>PCSK1 N221D</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Obesity</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

